Additionally, NEU3 is a promising biomarker for evaluating EGFR-targeted therapies in patients with NSCLC (85), and the expression level of GTs in lung cancer tumors may act as a biomarker for the diagnosis, prognosis, and treatment assessment (Table 2). Here, NEU3 is linked to non-small cell lung carcinoma.